{"id":"https://genegraph.clinicalgenome.org/r/6421eae8-62ed-4ffb-a9ce-3d9b2f1a702ev1.0","type":"EvidenceStrengthAssertion","dc:description":"*FIG4* was first reported in relation to autosomal dominant amyotrophic lateral sclerosis (ALS) type 11 in 2009 (Chow CY, et al., 2009, PMID: 19118816 ). ALS causes progressive degeneration of nerve cells in the spinal cord and brain. Dysfunctional endo-lysosomal and autophagic trafficking, leading to impaired proteostasis is common across ALS related genes. *FIG4*, also known as *SAC3*, is a phosphoinositide 5-phosphatase that regulates the cellular abundance of PI(3,5)P2, a signaling lipid located on the cytosolic surface of membranes of the late endosomal compartment. Evidence supporting this gene-disease relationship includes case-level data and experimental data. At least 16 rare variants have been reported in relation to ALS11. These variants have been reported in 16 probands across 8 publications (PMIDs: 19118816, 25299611, 25382069, 26742954, 27790088, 28051077, 35021275, and 29411640). Experimentally, this gene-disease relationship is supported by the role of *FIG4* in early endosome dynamics (PMID: 17556371 and 22157617) as well as model organisms with some overlapping features (PMID: 19793721 and 26708557). In summary, there is limited evidence to support this gene-disease relationship. While more evidence is needed to establish this relationship definitively, no convincing contradictory evidence has emerged.\n\nOf note, *FIG4* has also been reported in relation to Charcot-Marie-Tooth disease, type 4J (CMT4J), Yunis-Varon syndrome, and autosomal recessive polymicrogyria. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found ALS to be a distinct disease entity due to the autosomal dominant inheritance and differences in phenotype. It was curated separately from the additional disease entities. CMT4J and Yunis-Varon Syndrome, which are generally autosomal recessive, are on a single spectrum of severity with overlapping phenotypes and variants, and similar molecular mechanisms, therefore these entities were lumped together in a single curation performed by the Charcot-Marie-Tooth GCEP. Autosomal recessive polymicrogyria is an additional, distinct early onset seizure disorder, outside the scope of the ALS GCEP.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/6421eae8-62ed-4ffb-a9ce-3d9b2f1a702e","GCISnapshot":"https://genegraph.clinicalgenome.org/r/d038fb84-1f98-4047-b6c5-039a53756775","calculatedEvidenceStrength":"Limited","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/d038fb84-1f98-4047-b6c5-039a53756775_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10096","date":"2022-08-09T19:12:35.495Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/d038fb84-1f98-4047-b6c5-039a53756775_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10096","date":"2022-08-09T16:00:00.000Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d038fb84-1f98-4047-b6c5-039a53756775_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a0a23a96-8cac-434a-8ef3-84671550c0ad","type":"EvidenceLine","dc:description":"Because of the candidate gene sequencing approach additional ALS related genes have not been excluded.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a0a23a96-8cac-434a-8ef3-84671550c0ad_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Tested the ability of variant FIG4 to rescue the enlarged vacuole in a Fig4Δ null yeast strain. R388G had significantly less activity than the wild-type allele (p < 0.02).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/a0a23a96-8cac-434a-8ef3-84671550c0ad_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19118816","allele":{"id":"https://genegraph.clinicalgenome.org/r/11046422-52c8-49b7-8079-1297881c3860","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014845.6(FIG4):c.1162A>G (p.Arg388Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365225071"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/5d78503f-6b2b-46e7-a98d-d9653c154561","type":"EvidenceLine","dc:description":"The authors consider the pathogenicity of D48G to be uncertain.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5d78503f-6b2b-46e7-a98d-d9653c154561_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Tested the ability of variant FIG4 to rescue the enlarged vacuole in a Fig4Δ null yeast strain. D48G activity was comparable to the wild-type allele (p value 0.15).","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/5d78503f-6b2b-46e7-a98d-d9653c154561_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19118816","allele":{"id":"https://genegraph.clinicalgenome.org/r/9e887fce-e1d3-47ac-8a55-d3ccff73c98e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014845.6(FIG4):c.143A>G (p.Asp48Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365211566"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/cc68d829-e2f6-4f29-9136-93fe76280e82","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cc68d829-e2f6-4f29-9136-93fe76280e82_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28051077","allele":{"id":"https://genegraph.clinicalgenome.org/r/f7567488-395b-4915-95b9-9067977ea4f4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014845.6(FIG4):c.1619C>T (p.Thr540Ile)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA16044162"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/ae315b70-0066-44c4-8a00-cfd5952ad24a","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ae315b70-0066-44c4-8a00-cfd5952ad24a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19118816","allele":{"id":"https://genegraph.clinicalgenome.org/r/d8eb84a4-e0d8-4ae1-ab3d-d4b930a092fa","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014845.6(FIG4):c.2705T>C (p.Ile902Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/1415800"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/5d27d0f0-1723-4b1b-9cda-a97f987feb03","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5d27d0f0-1723-4b1b-9cda-a97f987feb03_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26742954","allele":{"id":"https://genegraph.clinicalgenome.org/r/81c98cd4-866e-400a-bca1-6514b840c81c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014845.6(FIG4):c.1147A>C (p.Lys383Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365225002"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/e4325b5b-7ba1-4639-bd5d-6fa261c3b551","type":"EvidenceLine","dc:description":"The Gln403Ter nonsense variant is in exon 11 of 23, upstream of the phosphatase active site, and is predicted to cause NMD. Loss of function has not been well-established s the mechanism for causing ALS so predicted null variants will not be scored higher than missense variants.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e4325b5b-7ba1-4639-bd5d-6fa261c3b551_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19118816","allele":{"id":"https://genegraph.clinicalgenome.org/r/74425803-9056-4d9d-a212-b352b5970d7e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014845.6(FIG4):c.1207C>T (p.Gln403Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10584275"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/e5890318-6ffb-4fda-832c-7db24dc0d095","type":"EvidenceLine","dc:description":"Nonsense variant in exon 19 of 23, predicted to cause NMD.\n\nLoss of function has not been well-established s the mechanism for causing ALS so predicted null variants will not be scored higher than missense variants.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e5890318-6ffb-4fda-832c-7db24dc0d095_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35021275","allele":{"id":"https://genegraph.clinicalgenome.org/r/76033e5d-1bd1-4ef5-be4d-c75e6a7d5c01","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014845.6(FIG4):c.2158G>T (p.Glu720Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365232320"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/3b371f57-39b3-4cf8-8ebe-9820fe9b4061","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3b371f57-39b3-4cf8-8ebe-9820fe9b4061_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26742954","allele":{"id":"https://genegraph.clinicalgenome.org/r/4ed28f3e-bc0e-44d8-99e4-8522472a1fc8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014845.6(FIG4):c.397A>G (p.Ile133Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/1515492"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/d5911720-7c0b-4473-9738-68868b85f973","type":"EvidenceLine","dc:description":"Nonsense variant in exon 15 or 23 is predicted to cause NMD.\n\nLoss of function has not been well-established s the mechanism for causing ALS so predicted null variants will not be scored higher than missense variants.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d5911720-7c0b-4473-9738-68868b85f973_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25382069","allele":{"id":"https://genegraph.clinicalgenome.org/r/56fd1960-651e-467a-a565-0d8b48c5940b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014845.5(FIG4):c.1589_1590del (p.Phe530Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA570036192"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/20039373-4a51-4b10-821f-a75ff9e2c868","type":"EvidenceLine","dc:description":"gnomAD non-neuro total AF 0.000004805","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/20039373-4a51-4b10-821f-a75ff9e2c868_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29411640","allele":{"id":"https://genegraph.clinicalgenome.org/r/11ebc650-48a3-4482-9322-b7864db7bdba","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014845.6(FIG4):c.2063A>G (p.Asp688Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365231957"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/2a0871dc-d350-4ae3-9fab-9d7a2b9c1d97","type":"EvidenceLine","dc:description":"The c.67−1G>T exon 2 splice acceptor variant is predicted to create a novel out-of-frame consensus acceptor site 2 bp downstream of the original site. This would result in the protein truncation R23fsX30. Alternatively, skipping of exon 2 would result in an in-frame deletion of 33 amino acids, likely to interfere with protein function. However, patient cells were not available for analysis of splice products and functional impact was not assessed.\n\nLoss of function has not been well-established s the mechanism for causing ALS so predicted null variants will not be scored higher than missense variants.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2a0871dc-d350-4ae3-9fab-9d7a2b9c1d97_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19118816","allele":{"id":"https://genegraph.clinicalgenome.org/r/946674ce-6564-4463-99f4-c4cca91cec96","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000006.12:g.109715077G>T (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365211012"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/ba38bf53-1362-40dd-a8ed-99c932df2cfd","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ba38bf53-1362-40dd-a8ed-99c932df2cfd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35021275","allele":{"id":"https://genegraph.clinicalgenome.org/r/6c4043b3-b400-4739-af1c-c10f0a0f4c48","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014845.6(FIG4):c.352G>T (p.Asp118Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365216111"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/bb39f017-a760-4e49-bdc2-5a2046d05cd7","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bb39f017-a760-4e49-bdc2-5a2046d05cd7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25382069","allele":{"id":"https://genegraph.clinicalgenome.org/r/b7daebd2-97bf-4a7d-9970-66cf94333860","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014845.5(FIG4):c.1228A>C (p.Thr410Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365225417"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/3329f141-a9cf-4b9f-8026-e21c75efa64c","type":"EvidenceLine","dc:description":"Because of the candidate gene sequencing approach additional ALS related genes have not been excluded.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3329f141-a9cf-4b9f-8026-e21c75efa64c_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Tested the ability of variant FIG4 to rescue the enlarged vacuole in a Fig4Δ null yeast strain. D53Y had significantly less activity than the wild-type allele (p < 0.001).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/3329f141-a9cf-4b9f-8026-e21c75efa64c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19118816","allele":{"id":"https://genegraph.clinicalgenome.org/r/7f851066-db29-4222-b14f-2680d44d076d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014845.6(FIG4):c.157G>T (p.Asp53Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA251934"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/e4c604b8-148f-44a1-bf3a-324b11949e7c","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e4c604b8-148f-44a1-bf3a-324b11949e7c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27790088","allele":{"id":"https://genegraph.clinicalgenome.org/r/6eab4306-51cb-4dbc-91a6-6eb2c63df8af","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014845.6(FIG4):c.1910C>A (p.Pro637Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365231587"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/e15419bc-daf0-4b91-877f-7af91945f9ac","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e15419bc-daf0-4b91-877f-7af91945f9ac_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25299611","allele":{"id":"https://genegraph.clinicalgenome.org/r/f0550e2a-8dd2-4695-8cab-84b4e20c843b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014845.6(FIG4):c.835T>C (p.Phe279Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365220912"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":1.6},{"id":"https://genegraph.clinicalgenome.org/r/d038fb84-1f98-4047-b6c5-039a53756775_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d038fb84-1f98-4047-b6c5-039a53756775_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0609bfd0-3b29-42f4-aa9d-a2670e5eb01f","type":"EvidenceLine","dc:description":"To clarify whether or not disruption of the physiological functions of dFIG4 are critical for the development of neurodegeneration, the authors established fly models in which the dFIG4 gene is knocked down. \n\nThe model is not specific to ALS and may represent the pathology of CMT.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/39bfa54c-02c8-40db-8b81-9e82a34efba2","type":"Finding","dc:description":"neuron-specific knockdown of dFIG4 affected the life span of the dFIG4-knockdown flies and reduced the climbing abilities of adult flies","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26708557","rdfs:label":"Fly knockdown","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/fb60c885-31e0-47f6-963e-bf678ecb3ca3","type":"EvidenceLine","dc:description":"Pale tremor mice have an AR inherited disorder, with phenotypes reminiscent of Charcot-Marie-Tooth disease. Overall, the mouse does not model ALS but there is still some support for how FIG4 could relate to ALS via the p62/ubiquitin inclusion bodies.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/52571adc-d1ad-44f4-84c7-2e7876f1a3dd","type":"Finding","dc:description":"p62/ubiquitin inclusion bodies are a hallmark of ALS. Detection of p62/ubiquitin inclusions in Fig4-deficient mice support the role of this gene in ALS.\n\nMarkers of autophagy are elevated in brain from Fig4−/− brain. To determine whether the elevated p62 in Fig4−/− brain is associated with ubiquitinated protein, brain slices were immunostained for p62 and ubiquitin. Co-localization of p62 and ubiquitin was evident in sections of the cortex and other regions of the brain.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19793721","rdfs:label":"Pale tremor mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":0.6},{"id":"https://genegraph.clinicalgenome.org/r/d038fb84-1f98-4047-b6c5-039a53756775_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7750ec98-29ec-4438-9da8-b904d5b36c3d","type":"EvidenceLine","dc:description":"The intrinsic phosphatase activity preferably hydrolyzed PtdIns(3,5)P2 in vitro, while ablation of endogenous Fig4 by siRNAs elevated PtdIns(3,5)P2 in 32P-labeled HEK293 cells.\n\nAdditionally, ectopically expressed Fig4WT in COS cells colocalized with and dilated EEA1-positive endosomes, consistent with the PtdIns(3,5)P2 requirement in early endosome dynamics. Suggesting that the tight regulation in PtdIns(3,5)P2 homeostasis is mechanistically linked to early endosome dynamics in the course of cargo transport.\n\nIt has not been established if the intrinsic phosphatase activity is directly related to the ALS phenotype observed in patients.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c1ccd4c4-0ec0-4d63-828c-11c875178cda","type":"Finding","dc:description":"Several of the gene defects that have been identified in ALS patients suggest a role for defective endosomal and receptor trafficking in the pathogenesis of this neuromuscular disease.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17556371","rdfs:label":"phosphoinositide 5-phosphatase","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/2f19d5b5-c3dc-48c4-94bc-f43405631dcd","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/623666d6-02f9-4c83-844c-f4f77a21c2a3","type":"Finding","dc:description":"Western blot was performed on developing mouse neuron tissues. In both the brain and the spinal cord, FIG4 was abundantly expressed but decreased later in development while it remained at a high level in sciatic nerves throughout development. In particular, this was observed at robust levels in myelinating neurons. RT-PCR analysis agreed with the above results. \n\nTo determine the subcellular localization of Fig4, the authors performed immunocytochemistry on rat mixed DRG and cortical cultures, finding that Fig4 predominantly resides in early endosomes .","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22157617","rdfs:label":"Expression in Nervous System","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":1.1}],"evidenceStrength":"Limited","sequence":4923,"specifiedBy":"GeneValidityCriteria9","strengthScore":2.7,"subject":{"id":"https://genegraph.clinicalgenome.org/r/dyajRmKzPRM","type":"GeneValidityProposition","disease":"obo:MONDO_0012945","gene":"hgnc:16873","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_d038fb84-1f98-4047-b6c5-039a53756775-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}